Hookipa Pharma (NASDAQ:HOOK) Rating Reiterated by HC Wainwright

Posted by Stephan Jacobs on Mar 28th, 2024

HC Wainwright reaffirmed their buy rating on shares of Hookipa Pharma (NASDAQ:HOOK – Free Report) in a research report released on Monday morning, Benzinga reports. They currently have a $6.50 target price on the stock. HC Wainwright also issued estimates for Hookipa Pharma’s Q1 2024 earnings at ($0.18) EPS, Q2 2024 earnings at ($0.07) EPS, Q3 2024 earnings at ($0.19) EPS, Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.60) EPS, FY2025 earnings at ($0.72) EPS, FY2026 earnings at ($0.67) EPS, FY2027 earnings at ($0.22) EPS and FY2028 earnings at $0.31 EPS.

Separately, Royal Bank of Canada lowered their target price on shares of Hookipa Pharma from $6.00 to $5.00 and set an outperform rating on the stock in a report on Tuesday, January 30th.

Get Our Latest Stock Analysis on Hookipa Pharma

Hookipa Pharma Stock Performance

Hookipa Pharma stock opened at $0.72 on Monday. The stock’s 50 day moving average is $0.70 and its 200-day moving average is $0.63. The company has a market capitalization of $60.48 million, a price-to-earnings ratio of -0.82 and a beta of 1.03. Hookipa Pharma has a 12 month low of $0.41 and a 12 month high of $2.05.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of HOOK. Jane Street Group LLC acquired a new position in shares of Hookipa Pharma during the fourth quarter worth $43,000. Virtu Financial LLC acquired a new position in shares of Hookipa Pharma in the second quarter valued at approximately $47,000. Two Sigma Investments LP bought a new position in Hookipa Pharma in the 3rd quarter valued at approximately $51,000. Mirabella Financial Services LLP acquired a new stake in Hookipa Pharma during the 1st quarter worth approximately $82,000. Finally, Alyeska Investment Group L.P. bought a new stake in Hookipa Pharma during the 4th quarter worth approximately $103,000. Institutional investors own 63.88% of the company’s stock.

Hookipa Pharma Company Profile

(Get Free Report)

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.